A Two-Part Phase 2/ 3 Multicentre, Double-Blind, Randomized, Placebo Controlled Study of Varlitinib Plus mFOLFOX6 Verses Placebo Plus mFOLFOX6 In Subjects With HER1/ HER2 Co Expressing Advanced or Metastatic Gastric Cancer Without Prior Exposure to Systemic Therapy
Active, no longer recruiting
Phase of Trial: Phase II/III
Latest Information Update: 11 Feb 2019
At a glance
- Drugs Varlitinib (Primary) ; Fluorouracil; Folinic acid; Oxaliplatin
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Registrational; Therapeutic Use
- Sponsors ASLAN Pharmaceuticals
- 06 Feb 2019 This trial has been Discontinued in Lithuania, according to European Clinical Trials Database.
- 29 Jan 2019 This trial has been Discontinued in Estonia.
- 13 Jan 2019 According to an ASLAN Pharmaceuticals media release, results from this trial will be presented at the Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology (ASCO GI).
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History